Azilsartan (EDARBI): A New Angiotensin Receptor Blocker (ARB) for Hypertension

Approved by the FDA for Marketing in the USA

Randa Hilal-Dandan

Disclosures

AccessMedicine from McGraw-Hill 

In This Article

Drug Interactions

In elderly patients, volume-depleted, or patients with compromised renal function, administration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or other selective COX-2 inhibitors with azilsartan may cause deterioration of renal function or renal failure. NSAIDs and COX-2 inhibitors also may attenuate the antihypertensive effect of azilsartan[2] (see Chapter 34 on NSAIDs).

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....